MXCT — MaxCyte, Inc.

Summary of MaxCyte, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $33 million for FY 2025, down 15% from $38.6 million in 2024.
• Q4 Revenue: $7.3 million, a 16% decline from $8.7 million in Q4 2024.
• Core Revenue: $29.6 million for FY 2025, down 9% from $32.5 million in 2024; Q4 core revenue was $6.8 million, down 22% year-over-year.
• Gross Margin: 78% in Q4 2025, up from 74% in Q4 2024.
• Operating Expenses: Reduced to $9 million in Q4 2025 from $19.3 million in Q4 2024, aided by restructuring efforts.
• Cash Position: Ended 2025 with $155.6 million in cash and no debt.

2. Strategic Updates and Business Highlights

• New Product Launch: Introduced ExPERT DTX, a modular 96-well electroporation platform aimed at enhancing early-stage research and drug discovery.
• Acquisition: Successfully integrated SecurDx, which is expected to contribute to revenue growth in 2026.
• Strategic Platform Licenses (SPLs): Continued to sign new SPLs, with 10 new agreements in the last 24 months, supporting 12 clinical programs across 11 partners.
• Milestone Payments: Received a seven-figure milestone payment from a clinical customer that began dosing patients in Q1 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected total revenue between $30 million and $32 million, with core revenue expected to be $25 million to $27 million.
• Q1 2026 Expectations: Anticipated to be the lightest quarter for core revenue, with a more robust performance expected in the second half of the year.
• SPL Program-Related Revenue: Expected to be $5 million in 2026, including $2 million from royalties.

4. Bad News, Challenges, or Points of Concern

• Customer Consolidation: Experienced a 15% decline in purchases from the largest customer due to program consolidation and inventory management.
• Loss of SPL Programs: Lost six SPL clinical programs in 2025, impacting revenue and leading to a projected $4 million headwind for 2026.
• Market Dynamics: Concerns raised about the trajectory of the business amidst improving trends in the biopharma sector, with questions about potential loss of market share.

5. Notable Q&A Insights

• Customer Sentiment: Management emphasized that current headwinds are not indicative of a deterioration in business fundamentals but rather short-term challenges.
• Future Growth: Confidence expressed in the upcoming pivotal studies and the potential for increased SPL signings, with expectations for three to five new agreements in 2026.
• Product Traction: Early traction for the ExPERT DTX noted, with expectations for revenue contributions to begin in the second half of 2026.
• Market Position: Management reiterated the company’s unique position in the market, highlighting the differentiation of their technology and the ongoing demand for their platforms.

Overall, while MaxCyte faced significant challenges in 2025, including revenue declines and customer consolidation, the company remains optimistic about future growth driven by new product launches, strategic partnerships, and a strong cash position.